University Clinical Hospital Virgen De La Arrixaca
- Address
- lock Available on a paid plan
Hematology and Blood Cancers
The University Clinical Hospital Virgen De La Arrixaca is running a strong program in hematologic malignancies and related blood disorders, with studies focused on follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, multiple myeloma, and myelofibrosis. These trials are mainly designed to test new treatment strategies, improve disease control, and extend remission for patients with relapsed, refractory, or newly diagnosed disease.
- Evaluating new approaches for follicular lymphoma and marginal zone lymphoma
- Testing therapies for diffuse large B-cell lymphoma and other aggressive blood cancers
- Studying treatment options in multiple myeloma and myelofibrosis
Research at this site also includes cell therapy and other advanced oncology approaches aimed at improving outcomes when standard treatments are no longer enough.
Breast and Gynecologic Oncology
Clinical research in breast cancer and ovarian cancer is a major focus in Murcia, covering early-stage, advanced, and recurrent disease. The studies explore better ways to prevent recurrence, strengthen endocrine treatment, and improve results for patients undergoing surgery and systemic therapy.
- Investigating therapies for early breast cancer, metastatic breast cancer, and triple-negative breast cancer
- Studying treatment strategies for advanced ovarian cancer and related gynecologic cancers
- Assessing new options to reduce recurrence and improve long-term disease control
Several trials also examine how to better match treatment to tumor biology, especially in hormone receptor-positive and HER2-negative disease.
Cardiovascular and Stroke Research
The site has an extensive portfolio in cardiovascular diseases and stroke prevention, including studies in atrial fibrillation, heart failure, coronary artery disease, and atherosclerotic cardiovascular disease. These trials are generally focused on preventing major events, improving heart function, and finding safer long-term treatment options.
- Testing therapies to lower the risk of stroke and systemic embolism
- Evaluating treatments for heart failure, hypertrophic cardiomyopathy, and dilated cardiomyopathy
- Studying prevention of major adverse cardiovascular events in high-risk patients
At University Clinical Hospital Virgen De La Arrixaca, this work reflects a broad effort to improve both early prevention and long-term cardiovascular care.
Neurology, Immunology, and Rare Disease Studies
Research in neurological and immune-mediated diseases includes studies in multiple sclerosis, acute ischemic stroke, amyotrophic lateral sclerosis, and graft-versus-host disease. The aim is to better control inflammation, protect nervous system function, and support recovery in difficult-to-treat conditions.
- Exploring new options for relapsing and progressive multiple sclerosis
- Assessing treatments for acute stroke and recovery after brain injury
- Studying therapies for steroid-refractory acute graft-versus-host disease and amyotrophic lateral sclerosis
These trials combine neurology and immunology research to address conditions with major unmet medical needs.
Respiratory, Infectious, and Metabolic Research
The trial portfolio also includes respiratory diseases, viral infections, and metabolic disorders, such as fibrotic lung disease, HIV-1, and hypertriglyceridemia. These studies are aimed at improving long-term safety, disease control, and prevention of complications.
- Evaluating treatments for fibrotic lung disease and chronic lung inflammation
- Studying long-term management in HIV-1
- Assessing therapies for hypertriglyceridemia and related cardiovascular risk
This mix of research shows the hospital’s broad interest in chronic disease management across several therapeutic areas.
Women’s Health, Pregnancy, and Hematologic Support
Additional studies at the site address female urogenital health, pregnancy complications, and inherited blood disorders. Current research includes preeclampsia prevention and treatment approaches for hemophilia, with a focus on safer care for women and patients with bleeding conditions.
- Preventing preterm preeclampsia and related pregnancy complications
- Evaluating supportive care for hemophilia A and hemophilia B
- Improving treatment safety in patients with inherited bleeding disorders
These studies broaden the research profile of University Clinical Hospital Virgen De La Arrixaca beyond oncology and cardiovascular care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 23 therapeutic areas and 15 of 563 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 536 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 128 by active trials.
lock +127 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG20trials
lock +71 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in University Clinical Hospital Virgen De La Arrixaca
lock Showing 1 of 359 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis | Biogen Idec Research Limited | Phase II | Not Recruiting | Oct 2023 | Feb 2026 |
IMP list
lock Showing 1 of 563 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 18 | Unknown | 2017-10-02 | 2025-05-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.